DCN Dx to Showcase New Technologies and Present Critical Research at ADLM 2024

Meet DCN Dx's Experts and Discover the miniDxR Customizable Lateral Flow Reader at Booth 2468

CARLSBAD, Calif., July 11, 2024 /PRNewswire/ -- DCN Dx, a global leader in IVD CDMO and CRO services, is excited to announce their participation in the ADLM Annual Meeting 2024 (formerly AACC) from July 28 to August 1 at the McCormick Place Convention Center in Chicago, IL. Attendees are invited to visit DCN Dx at booth 2468 to explore their latest innovations and join their poster presentation on quantitative bacteriology parameters.

DCN Dx will have representatives from their assay development, engineering, clinical research, and manufacturing teams on hand to answer questions and discuss their comprehensive services. This multidisciplinary approach ensures that DCN Dx can support every stage of IVD product development, from concept through to manufacturing, including IVD clinical trials with particular expertise in point-of-care testing.

Attendees can also experience the miniDxR, a state-of-the-art customizable lateral flow assay reader, at the DCN Dx booth. Designed by DCN Dx for point-of-care testing, the miniDxR offers advanced imaging technology, superior sensitivity and specificity, and robust cybersecurity features, making it an ideal solution for a variety of settings.

The poster presentation will examine the performance of InTray® Mueller Hinton Chocolate and Colorex™ Screen agar plates under stress conditions mimicking low-resource tropical field clinics. This study, presented by Brandon Font, Research Scientist and Technical Services Manager at Biomed Diagnostics, a DCN Dx brand, and Pat Vaughan, Ph.D., COO of DCN Dx, evaluates the plates' ability to maintain bacterial viability and diagnostic accuracy over extended periods.

"We are excited to be back at the ADLM Annual Meeting this year," said Charlie Mamrak, CEO of DCN Dx. "Our poster presentation and the presence of our multidisciplinary team highlight our commitment to advancing diagnostic technologies for the clients we serve."

"Having our experts at the ADLM Annual Meeting allows us to host in-depth conversations in our booth," said Mitzi Rettinger, Chief Revenue Officer of DCN Dx. "Our team is ready to share how our services reduce risk for our clients' IVD programs and improve patient outcomes."

"Our research on the performance of InTray® agar plates under challenging conditions demonstrates our dedication to supporting diagnostic solutions in diverse conditions," said Dr. Pat Vaughan. "We look forward to discussing our findings with fellow attendees."

About DCN Dx

DCN Dx, based in Carlsbad, California, is a global leader in IVD CDMO and CRO services. Our multidisciplinary CDMO specializes in creating tailored assay systems, consumables, and instruments for point-of-use applications, with a particular expertise in lateral flow assays. Our clinical research services group specializes in the planning, execution, and oversight of IVD clinical trials, inclusive of clinical operations, data management, and biostatistics.

Our personalized approach to IVD product development and clinical trials has supported hundreds of programs and clients. We can oversee every stage from concept to assay development and platform integration, through clinical trials to manufacturing or only handle the aspects you request. In addition to lateral flow assays, our clinical research expertise extends to a wide range of IVD devices, all with a focus on innovation, usability, and performance.

With a commitment to quality, customer satisfaction, and industry-leading expertise, DCN Dx is setting the benchmark for excellence in IVD services. To learn more about how we can support your diagnostic needs, visit dcndx.com.

For more information contact:
Mitzi Rettinger
Chief Revenue Officer, DCN Dx
Main: (760) 804-3886
Mobile: (512) 431-5836
[email protected]

SOURCE DCN Dx